Could Newer Treatments Used As Frontline Treatment Decrease Future Efficacy of FCR?
Could using newer treatments, like ibrutinib (Imbruvica), as a frontline treatment decrease the future efficacy of FCR if the patient becomes refractory?... Learn More
2016 Patient Café: CLL and Dating
Can dating be an issue when you have CLL? Can you be holistically intimate with someone new in your life? Carol Preston,... Learn More
Patient Café 2016: How Are Romantic Relationships Impacted by CLL?
How does cancer impact romantic relationship? CLL patient advocate Carol Preston hosts this Patient Café, as Jennifer and Susan describe how their... Learn More
October 2016 CLL Patient Café: Meet the Participants
How does your CLL diagnosis impact your relationships? Patient Power host Carol Preston introduces four CLL patients in our Patient Café. Meet... Learn More
ASH 2015 Coverage: The Meaning of a Second-Generation BTK Inhibitor for Patients
Watch patient advocate Carol Preston, on location at the 2015 American Society of Hematology (ASH) conference, discusses the new molecule, ACP-196, a... Learn More
Recommendation for Diet During Watch and Wait
Are there any dietary suggestions or restrictions for patients in watch and wait? Patient Power founder, Andrew Schorr, asks CLL expert, Dr.... Learn More
The Power of the Virtual Connection
Why should patients join an online discussion group? Andrew Schorr, Patient Power founder and host, wraps up this Patient Café discussion with... Learn More
Dealing With Negative Messages on the Internet
Do negative messages you read on the Internet affect you? Do they make you more fearful of your diagnosis? Andrew Schorr, Patient... Learn More
Patient Café 2016: Finding Clinical Trials and CLL Specialists Online
Where can CLL patients find information about CLL specialists and clinical trials online? At the Patient Café, Patient Power founder and CLL... Learn More
Second-Generation CLL Inhibitors
How could patients benefit from second-generation CLL inhibitors? CLL experts Dr. Nicole Lamanna and Dr. Philip Thompson explore the top three reasons... Learn More
The Benefits of Connecting to the CLL Virtual Community
Should you connect with other CLL patients virtually? Andrew Schorr, Patient Power founder, met with three patients and a care partner to... Learn More
Transplant: When Should it Be Considered for CLL Patients
In treating CLL, where does transplant fit in? CLL experts Drs. Philip Thompson and Nicole Lamanna share their opinions on this topic.... Learn More
Venetoclax: Will It Be Approved for 11Q Deletion Patients?
Could venetoclax be used soon for patients with 11q deletion? Dr. Nicole Lamanna of Columbia University Medical Center, answers a viewer’s question... Learn More
Cosmetic Procedures: Are They Safe for CLL Patients?
Are cosmetic procedures considered safe for chronic lymphocytic leukemia (CLL) patients? CLL expert Dr. Nicole Lamanna answers this question. Dr. Lamanna stresses... Learn More
How Do Autoimmune Diseases Affect CLL?
Dr. Nicole Lamanna, a CLL specialist at Columbia University Medical Center, answers a question about treatment options for CLL patients with autoimmune... Learn More
2016 Patient Café: Sharing Our Advice With Other Patients
You’ve been diagnosed with cancer. What do I do now? Patient Power Host, Carol Preston, leads this positive discussion on advice to... Learn More
Coping With the Emotional Side of CLL
How can patients best cope with emotional changes? Patient advocate Carol Preston hosts this Patient Café as Elaine, Jay, Derek and Lisa... Learn More
Will Venetoclax’s Approval Be Expanded to a Broader Group of Patients?
Will the recently approved treatment venetoclax (Venclexta) be available soon for all CLL patients? Andrew Schorr, Patient Power founder and host, asks... Learn More
2016 Patient Café: How to Be An Effective Member of Your Healthcare Team
Carol Preston, Patient Power Host and CLL Patient, moderates a discussion on how to be an effective member of your own cancer... Learn More
Could Combining Inhibitors and Antibodies Improve Response Rates?
Could inhibitor treatments be used in combination with antibodies to improve complete response rates? Dr. Philip Thompson of MD Anderson Cancer Center... Learn More
LDH: What Is It?
What are LDH levels and what is their importance? Dr. Philip Thompson, a CLL expert from MD Anderson Cancer Center, answers a... Learn More
Why Does CLL Vary?
Why does CLL vary between patients? Andrew Schorr, Patient Power founder and host, delves into this question with two CLL specialists, Dr.... Learn More
CLL and SLL: What’s the Difference?
What is the difference between being diagnosed with SLL versus CLL? Patient Power host, Andrew Schorr, asks Dr. Nicole Lamanna, a CLL... Learn More
Jennifer Abraham: How I Adjusted My Sails After a CLL Diagnosis
Andrew Schorr, Patient Power founder and host, interviews three-time cancer survivor, Jennifer Abraham. Jennifer decided to view her life with cancer as... Learn More
CLL Research Update From ASCO 2016
What developing research released at ASCO this year do CLL patients need to know about? Dr. Jeff Sharman, a leading CLL expert,... Learn More
MRD-Negative Status: What Does It Mean?
Andrew Schorr, two-time cancer survivor and Patient Power host, speaks candidly with Dr. Philip Thompson, to explore MRD (minimal residual disease) negativity... Learn More
Body Aches and CLL
Could body and joint aches a symptom of CLL? Dr. Philip Thompson of MD Anderson Cancer Center answers this viewer question in... Learn More
Personalizing CLL Treatment
Is it possible to get the best treatment for my CLL even if I am not seeing a specialist? Andrew Schorr, who... Learn More
Considerations for a Bone Marrow Transplant
What are the pros and cons of continuing CLL therapies versus having a bone marrow transplant (BMT)? CLL expert Dr. Philip Thompson... Learn More
Living Well With CLL Town Meeting Afternoon Replay
Watch the replay of the afternoon session of our “Living Well with CLL” town meeting to learn hear a panel of experts... Learn More
Living Well With CLL Town Meeting Replay
In the replay of the morning session of our “Living Well with CLL” town meeting, experts Dr. Nicole Lamanna and Dr. Philip... Learn More
Is My Fatigue From My CLL?
For many, fatigue is the most common symptom of CLL. CLL expert Dr. Philip Thompson, from MD Anderson Cancer Center, answers a... Learn More
Where Is Treatment Headed With Frontline CLL Treatment Approaches?
Dr. John Gribben, University of London, and Dr. Constantine Tam, Peter MacCallum Cancer Centre, join Patient Power Founder, Andrew Schorr, to discuss... Learn More
Bob Azopardi Patient Shares His Clinical Trial Experience
Are patients that participate in clinical trials pioneers? Andrew Schorr, Patient Power Founder, interviewed Bob Azopardi, a 16-year CLL patient who participated... Learn More
The CLL Treatment Landscape: How Is It Evolving?
Patient Power Founder and host, Andrew Schorr interviews CLL expert Dr. Richard Furman to discuss the evolving CLL treatment landscape, including the... Learn More
Are Vaccinations Safe for CLL Patients?
Is it safe for CLL patients to get vaccinations? Are there risks involved? Andrew Schorr asks CLL expert Dr. Nicole Lamanna about... Learn More
Breaking News: Expert Perspective on Venclexta (venetoclax) Approval
The U.S. Food and Drug Administration (FDA) has approved a new drug Venclexta (venetoclax) for use in CLL patients with the 17p... Learn More
What Could a New Drug Approval Mean for CLL Patients?
Dr. William Wierda, medical director of the Department of Leukemia at the University of Texas MD Anderson Cancer Center, joins Patient Power... Learn More
CLL and Travel: What’s Safe?
CLL patients have compromised immune systems, so is it safe to travel? CLL expert Dr. Michael Keating, of MD Anderson Cancer Center,... Learn More
Living Well With CLL: What Does It Mean?
It’s easy to focus on getting or staying physically healthy while living with CLL but what about your overall health? An expert... Learn More
Do Supplements Help or Harm CLL Patients?
For people with CLL, are supplements safe? Could they help fight CLL? In this segment, Patient Power founder Andrew Schorr poses these... Learn More
Breaking News: Gilead Sciences Halts Six Idelalisib Combination Trials
After serious adverse events were reported in patients, Gilead Sciences, Inc. has halted six clinical trials using idelalisib in combination with other... Learn More
CLL Treatment Combinations for Optimal Effects
Why are researchers and physicians so excited about combination CLL therapy? Patient Power Founder Andrew Schorr sits down with CLL experts Dr.... Learn More
Immunotherapy and CLL: An Expert Panel Discussion
Immunotherapy is personalized therapy for people with cancer–but can it outsmart CLL? Experts Drs. John Gribben, Constantine Tam,and William Wierda, along with... Learn More
How Are Monoclonal Antibodies Used?
What are monoclonal antibodies, and how are they used to treat CLL? From MD Anderson Cancer Center, Drs. Zeev Estrov and Michael... Learn More
Understanding Emerging CLL Immunotherapy Options
Understanding all of the emerging immunotherapy options for CLL patients can be difficult. Drs. Zeev Estrov, Michael Keating, and Nicole Lamanna explore... Learn More
CLL Treatment Side Effects: Managing and Monitoring
Is it really important to mention treatment side effects to your healthcare team? CLL expert Dr. Nicole Lamanna of Columbia University Medical... Learn More
Michele Vlog 2
Patient Power contributor and CLL patient Michele Nadeem-Baker shares the second in a series of personal video blogs as she reports on... Learn More
How Do Genetic Testing and Targeted Therapy Fit in CLL?
Dr. Michael Keating of MD Anderson and Dr. Nicole Lamanna of Columbia University give a thorough description of FISH and CLL profiling,... Learn More
Should Genetic Tests Be Repeated?
Patient Power founder Andrew Schorr visits with Dr. Michael Keating of MD Anderson Cancer Center to ask audience questions about repeat genetic... Learn More
Reflections on ASH 2015 From Dr. Susan O’Brien
On location at the American Society of Hematology (ASH) 2015 meeting, CLL expert Dr. Susan O’Brien of the University of California, Irvine,... Learn More
Is There Still a Place for Chemo in CLL?
Which CLL patients benefit most from chemotherapy? CLL expert Dr. Nicole Lamanna explains the various therapeutic agents currently in use, who they... Learn More
An Expert Update on Treating CLL With Immunotherapy
Where do we stand with CAR-T therapy? Could checkpoint inhibitors apply in CLL? CLL expert Dr. William Wierda, from the 2015 American... Learn More
ROR1: An Update
Patient Power founder, Andrew Schorr, caught up with CLL expert Dr. Thomas Kipps at the 2015 American Society of Hematology (ASH) meeting... Learn More
Does CLL Return More Aggressively After Relapse?
Dr. Michael Keating, from MD Anderson Cancer Center, joins us for another segment in our “Ask The Expert” series, answering a question... Learn More
ASH 2015: Emerging Combination Treatment Approaches
Dr. Andrew Zelenetz of Memorial Sloan Kettering Cancer Center describes the expanding CLL and lymphoma armamentarium on location at the 2015 American... Learn More
Understanding CLL Symptoms and Progression
CLL experts Drs. Zeev Estrov, Nicole Lamanna and Michael Keating at our town meeting at MD Anderson Cancer Center in Houston, Texas,... Learn More
About Melanoma Cancer Drug Keytruda ( Pembrolizumab )
Keytruda ( pembrolizumab ) is a new cancer drug to treat advanced melanoma, the deadliest form of skin cancer. An anti-body drug,... Learn More
PARP Inhibitors for Cancer Treatment – Part4
Oncologist Stephen Lemon continues his discussion on the use of PARP Inhibitors as a targeted therapy for the treatment of cancer. Visit... Learn More
PARP Inhibitors for Cancer Treatment – Part3
In cancer treatment, PARP Inhibitors is a targeted therapy which targets the exact genetic changes that make cancer cells so deadly, while... Learn More
PARP Inhibitors in Cancer Therapy – Part2
Dr. Lemon continues his discussion on PARP inhibitors in cancer treatment. PARP inhibitors are being evaluated as as a potential targeted therapy... Learn More
PARP Inhibitors for Cancer Treatment – Part1
Oncologist Stephen Lemon talks about PARP Inhibitors in the treatment of cancer. Because several forms of cancer are more dependent on PARP... Learn More
How Avastin (Bevacizumab) Treats Metastatic Breast Cancer
Medical oncologist Stephen Lemon MD presents a lecture on Avastin (bevacizumab) in the treatment of metastatic breast cancer. Visit http://www.lemonmd.com to learn... Learn More
How Breast Cancer Genetics Affect Treatment
In this lecture on breast cancer awareness, Dr. Stephen Lemon discusses the importance of genetics as a prognostic tool and how a... Learn More
How Colon Cancer Genetics Factor in Cancer Treatment
Omaha oncologist Dr. Stephen Lemon discusses the importance of genetics for the treatment and prevention of colorectal cancer, including colon and rectal... Learn More
What is Small Cell Lung Cancer?
About 12 out of every 100 lung cancers diagnosed are small cell lung cancer. So what is it? Oncologist Stephen Lemon discusses... Learn More
How Genetics Affect Breast Cancer Treatment
No two cases of breast cancer are exactly alike. Oncologist Stephen Lemon discusses how a patient’s unique genetics can help determine their... Learn More